生物标志物对抗血管生成药物疗效预测作用的进展

Chinese Clinical Oncology ›› 2018, Vol. 23 ›› Issue (10): 952-956.

Predictive biomarkers to antiangiogenesis therapies

Department of Medical Oncology, Cancer Center of PLA，the 81st Hospital Affiliated to Nanjing University of Chinese Medicine，Nanjing 210002

Received:2018-05-07 Revised:2018-08-17 Online:2018-10-31 Published:2019-03-20
Contact: WANG Lin E-mail:wanglin81yy@163.com

Abstract

Abstract: The development of new blood vessels not only serves to supply the tumor tissue with nutrients， but they can also serve as a means for cancer cells to metastasize. Anti-angiogenic therapy for cancer has gradually become an important way of cancer therapy. The widespread use of anti-angiogenic drugs in clinical practice not only brings benefits to patients but also brings side effects and economic burdens. Therefore more and more researches on predictive biomarkers to anti-angiogenesis therapies have been carried out. Some studies have found that vascular endothelial growth factor（VEGF）／vascular endothelial growth factor receptor（VEGFR） pathway related factors， cytokines of CXC chemokine family and other angiogenic regulators can predict the efficacy of anti-angiogenic drugs. However， the conclusions of different studies are not exactly the same， and the related predictors are not widely accepted. This article reviews the predictive effects of biomarkers on anti-angiogenic drugs.

Key words: font-family:宋体, Biomarker">Biomarkerfont-family:宋体, ')">">, Anti-angiogenic drugs, Effect, Predictor

CLC Number:

R730

XING Lijun, HUANG Wei, WANG Lin.. Predictive biomarkers to antiangiogenesis therapies[J].Chinese Clinical Oncology, 2018, 23(10): 952-956.

0
/ / Recommend Biomarker；Anti-angiogenic drugs；Effect；Predictor”. Please open it by linking:http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/abstract/abstract2558.shtml" name="neirong"> Biomarker；Anti-angiogenic drugs；Effect；Predictor">

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/

http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/Y2018/V23/I10/952

References

Related Articles 9

[1]	LI Zhenmiao, SONG Bo, ZHAO Yi.. Clinical observation on the long-term survival and immune function of breast-conserving surgery with X-ray intensity-modulated radiotherapy [J]. Chinese Clinical Oncology, 2019, 24(2): 158-162.
[2]	YAO Jiayu, WU Xia.. Financial toxicity： An overlooked problem in the era of molecular and immune therapy of cancer treatment [J]. Chinese Clinical Oncology, 2019, 24(2): 183-187.
[3]	GE Qin, QIAN Xia, XIE Guodong, CAI Jing, YANG Baixia, WU Jianting, ZHAO Jizhong, CUI Juanjuan, ZHU Xinghua, CHU Chunxia. . The effect of EGFR and TGF-α in radiosensitization of lung cancer cells [J]. Chinese Clinical Oncology, 2019, 24(2): 145-148.
[4]	. [J]. Chinese Clinical Oncology, 2018, 23(10): 937-944.
[5]	XU Jing, LI Jie, ZHANG Meijing, CHEN Longpei, LONG fei, WANG Wei, ZHAN Xianbao.. Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting： A retrospective study in changhai hospital [J]. Chinese Clinical Oncology, 2018, 23(5): 440-443.
[6]	MAO Haiyan, LIU Siping, ZHANG Lei, TONG Jiandong, BO Ping. . The biological effects of neuropilin-1 in the development of gastrointestinal cancers [J]. Chinese Clinical Oncology, 2018, 23(5): 467-471.
[7]	MEI Wenjuan, LI Xin, WU Xiaoyan, ZHANG Zhoulong. . The value of acoustic radiation force impulse imaging in differentiating benign and malignant thyroid nodules [J]. Chinese Clinical Oncology, 2018, 23(5): 444-448.
[8]	LIU Yuchen, WU Bin.. A review of value assessment frameworks of antitumor drugs in foreign countries [J]. Chinese Clinical Oncology, 2018, 23(5): 472-475.
[9]	. Ｐｒｏｇｒｅｓｓｉｏｎｏｆｍｏｎｏｃｏｌｏｎａｌａｎｔｉｂｏｄｉｅｓｆｏｒｃｏｌｏｒｅｃｔａｌｃａｎｃｅｒｉｎ 2008 [J]. Chinese Clinical Oncology, 2009, 14(1): 1-.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!